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FORWARD 
The Scientific Committee on CosmetoLogy was set up by Commission Decision 
47/45/EEC on 19 December 1977 (OJ N° L 13 of 17 January 1978, p. 24) in 
order to provide the Commission with informed opinions on any scientific and 
technical problems arising in connection with cosmetic products, and in 
particular on the substances used in their manufacture, on their composition 
and on the conditions for their use. 
The members of the Committee are independent scientists highly qualified in 
the fields of medicine, toxicology, biology, chemistry or other similar 
disciplines. 
The Committee is serviced by the Directorate-general for the environment, 
consumer protection and nuclear safety. 
This volume contains a collection of the Committee's fifth reports setting 
out the opinions it delivered on the dates given in the headings. 
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REPORT OF THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
CONCERNING THE USE OF N-(HYDROXYMETHYL)-N-(1,3-DIHYDROXYMETHYL-2,5-
DI0X0-4-IMIDAZ0LIDINYL)-N'-(HYDR0XYMETHYL) UREA AS A PRESERVATIVE 
(Opinion delivered on 25 March 1985) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give an opinion on the use of N-(hydroxymethyl)-N-(1,3-dihydroxymethyl-2,5-
dioxo-^-imidazolidinyD-N'-Chydroxymethyl) urea as a preservative at a maximum 
concentration of 0.5% in the finished cosmetic product. 
CONCLUSION 
The Committee requests further tests on N-(hydroxymethyl)-N-(1,3-
dihydroxymethyL-2^5-dioxo-4-imidazoLidinyL)-N,-(hydroxymethyl) urea to examine 
genotoxic properties and to establish the type of systemic toxicity upon 
sufficiently high oral exposure, and on the amount of formaldehyde released 
from this substance. On the basis of the existing data, however, it can approve 
the provisional use of N-(hydroxymethyl)-N-(1,3-dihydroxymethyl-2,5-dioxo-4-
imidazolidinyl)-N'-(hydroxymethyl) urea as a preservative in cosmetics at a 
maximum concentration of 0.5 X in the finished product. 
BACKGROUND 
1. Council Directive 76/768/EEC on the approximation of the laws of the Member 
States relating to cosmetic products, as last amended by Council Directive 
84/415/EEC, authorizes the placing on the market of cosmetic products 
containing as a preservative only the substances listed in Annex VI to the 
said directive, within the limits and concentrations specified therein. 
2. The industry has requested that N-(hydroxymethyl)-N-(1,3-dihydroxymethyl-
2,5-dioxo-4-imidazolidinyl)-N'-(hydroxymethyl) urea be added to that Annex 
as a new preservative agent in the cosmetic products and has submitted a 
scientific dossier in support of its request. 
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3. The Committee is consequently invited to express an opinion on the use of 
N- (hydroxy methyl)-N-(1,3-di hydroxy methyl-2,5-di oxo-4-imidazol idi nyU-N'-
(hydroxymethyl) urea as a preservative at a maximum concentration of 0.5% in 
the finished cosmetic product. 
DISCUSSION 
4. Chemical name : N-(hydroxymethyl)-N-(1,3-dihydroxymethyl-2,5-dioxo-4-
imidazolidinyO-N'-ChydroxymethyO-urea 
CH-.0H 
I 
I 
N ■■ CH20H 
KH I 
CH20H 
CH20H C8HUN4O7 
DU 278.23 
5. Synonyms : Diazolidinylurea, Germai I I 
6. Soluble in water; insoluble in most organic solvents. 
7. This substance is known to release formaldehyde, the maximum amount being 
10 %, as determined by a destructive method. 
8. Use level up to 0.5%. 
9. The oral LD5Q in rats was 2570 mg/kg. 
The dermal L D „ in rabbits, when applied undiluted as a powder, was 
> 2000 mg/kg. 
10. Skin irritation tests in rabbits with 0.5 ml of 1.0% and 5.0% solutions in 
water were negative. 
11. An eye irritation test in rabbits with 0.1 ml of 1.0 and 5.0% aqueous 
solutions did not induce any changes. 
- 2 -
12. In a sensitization test In guinea pigs by the Landsteiner-Draize method, the 
induction treatment consisted of 10 intracutaneous injections of 0.1 ml 0.1% 
in saline solution. After a 2 weeks rest period, 0.05 ml of a 0.1% solution 
was given intracutaneously as a challenge. The test was considered 
negative. 
13. In a maximization test in guinea pigs induction was performed with the 
undiluted substance applied topically and with a 5% solution applied intra-
dermally. The Induction areas were pretreated with sodium lauryl sulphate. 
The response to the challenge treatment, conducted 2 weeks later, suggested 
the test substance to be a weak sensitizer. 
14. Phototoxicity tests in groups of 9-11 human subjects with 0.2 g sunscreen 
cream or sunscreen lotion containing 0.5% diazolidinyl urea, did not induce 
signs of phototoxicity, when applied 10 times on a closed patch for 24 
hours, followed by UV- or UV-A-irradiation at a distance of 10 cm during 15 
minutes. A similar phototoxicity test In 11 subjects with one application of 
0.2 g sunscreen lotion containing 0.5% and irradiated with UV-A was likewise 
negative. 
15. A sensitization study in 110 women was conducted with a sunscreen 
formulation containing 0.25% of the preservative applied with 10 successive 
patches under semi-occlusion. The challenge patch with the same 
formulation, after a 2 week rest, resulted in only one dubious, positive 
reaction. 
No cross-sensi ti zat ion was observed in 71 patients (who had shown 
sensitization to various preservatives and other chemicals) upon patch 
testing with 0.5 and 1.0% Germall II in water and in petrolatum. 
16. In several photosensitlzation tests, groups of 28-30 human subjects were 
treated with 0.2 g of 0.5% in a sunscreen cream, or in a sunscreen lotion 10 
times, each time for 24 hours and each treatment followed by UV-, UV-A, or 
UV-B-irradiation for 15 minutes. After a 10-18 days rest period, the 
challenge treatment with an occluded patch for 24 hours followed by UV, UV-A 
or UV-B-irradiation did not reveal photoallergic properties, although one 
slight transient reaction was observed. 
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A skin cleanser with 0.3 X was examined in a prophetic patch test on 104 
subjects and in a repeat insult patch test on 52 subjects. No positive 
reactions were observed. 
17. In a 90-day oral rat study the test substance was fed in the diet at levels 
providing 0, 10, 25 or 100 mg/kg bw. There were no treatment-related 
changes in growth rate, haematology and clinical chemistry or in the results 
of the pathological examinations. Therefore, 100 mg/kg was considered to be 
a no-toxic effect level. 
18. The Ames test, which was conducted repeatedly with dose levels up to 
800 ¿il/plate showed signs of a positive response, but the results were 
inconclusive. 
19. The Committee requests further tests to examine genotoxic properties and to 
establish the type of systemic toxicity upon sufficiently high oral exposure 
and information on the amount of formaldehyde released from this substance. 
20. On the base of the existing data, however, it can approve the provisional 
use of N-(hydroxymethyl)-N-(1,3-dihydroxymethyl-2,5-dioxo-4-
imidazolidinyO-N'- (hydroxymethyl) urea as a preservative in cosmetics at a 
maximum concentration of 0.5% in the finished product. 
21. Information : Co li pa dossier, Submission I, January 6, 1983 
II, April 14, 1983 N 
N 
n 
H 
III, December 12, 1983 
IV, June 3, 1985 
V, June 3, 1985 
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REPORT BY THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
CONCERNING THE USE OF ETIDRONIC ACID AND SALTS 
THEREOF IN COSMETIC PRODUCTS 
(Opinion delivered on 25 June 1985) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give its opinion concerning the use of etidronic acid and salts thereof 
in oral-hygiene products, hair -care products and soaps. 
CONCLUSION 
The Committee considered that the use of etidronic acid and its salts in 
mouthwash products, hair-care products and soaps did not constitute a 
health risk if such use were in accordance with the restrictions and 
conditions set out in paragraph 2. Only a majority of the members were able 
to recommend the use of etidronic acid and its salts in toothpastes. 
BACKGROUND 
1. Council Directive 76/768/EEC on the approximation of the laws of the 
Member States relating to cosmetic products, as last amended by 
Directive 84/415/EEC, contains no special provisions to govern etidronic 
acid and salts thereof. 
2. One Member State has suggested that the use in cosmetic products of 
etidronic acid and salts thereof, which are substances which exert a 
medicinal effect, be made subject to the following conditions and 
restrictions : 
Field of application 
and/or use 
Toothpastes 
Oral-hygiene products 
Hair-care products 
Soaps 
Maximum authorized concentration 
in the finished product 
0.5% ) 
1.0% ) 
1.5% ) 
0.2% ) 
Expressed 
as 
acid 
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3. The Committee was therefore requested to express an opinion concerning 
the use of etidronic acid and salts thereof in cosmetic products in 
accordance with the proposed conditions. 
DISCUSSION 
4. Since etidronic acid (HEDP) exerts a marked effect on calcium 
metabolism, it would be necessary to have precise knowledge of the 
purity criteria, because the presence of any fluorine of phosporic 
origin would play an important part in the assimilation and elimination 
of calcium. 
5. HEDP exists as an acid, as a di sodium salt and as a dicalcium salt. 
Most of the toxicity tests were carried out on the disodium salt, but in 
the acute-toxicity and absorption studies all three forms were tested. 
6. The oral LDc« results varied between 1 g/kg and 11 g/kg, according to 
the species of animal and the form tested; the dicalcium salt proved to 
be the least toxic. When the intraperitoneal route was used in mice, 
the LD_Q was 0.285 g/kg with the acid form. 
7. Intestinal absorption after oral administration varied between |0.6 and 
13.6|, according to the species. The sparingly soluble dicalcium salt 
was absorbed only at the rate of 0.08% (2% of the absorption rate of the 
disodium salt). In man, absorption increases in proportion to the dose 
ingested. Approximately 10% of the absorbed dose was found in the 
skeleton, the rate of accumulation varying with the age of the animal. 
HEDP in an untransformed state was excreted in the faeces and the urine. 
8. At a low dose, HEDP appeared to encourage assimilation of Ca in the 
bones. At a high dose, increased absorption by the intestinal tract 
accompanied by increased urinary excretion of Ca resulted in a 
reduction both of Ca retention and of bone Ca . Inhibition of the 
mineralization of epiphyseal cartilage was observed. It would be 
advisable to ascertain the borderline between the beneficial and the 
adverse effects of this substance in the organism. 
9. HEDP had a slightly irritant effect on the eyes and skin. It reacted 
positively to a Magnusson and Kligman maximization test (5/25). 
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10. In the acute subcutaneous toxicity studies in rats, an adverse influence 
was observed on the formation of bony tissue at doses of 2 mg/kg 
b.w./day or more. Administration of 0.2 and 0.4 mg/kg b.w./day caused 
an increase in hard tissue resulting from reduced absorption without any 
change in the effect on formation. 
11. In acute oral tests in cats and rats, the main effects observed were 
dose-related renal ones, changes in bony tissue and considerable 
fluctuations in blood calcium and phosphorus levels. In rats, the no-
effect level (NEL) was 100 mg/kg b.w./day. 
12. Chronic (two years) oral administration of 0.25-100 and 500 mg/kg 
b.w./day had no carcinogenic effect in rats. The no-effect level, as 
regards the blood picture and urine and blood chemistry, appeared to be 
25 mg/kg b.w./day. It was noted that the test took no account of the 
composition of bony tissue. 
13. An oral-route reproduction and teratogenicity study on two generations 
of rats revealed an effect on reproduction when 250 mg/kg b.w. was 
administered; a reduction in the number of implants and corpora Lutea 
was observed. The no-effect dose was 50 mg/kg b.w. 
14. Several oral-route teratogenicity studies in rats and rabbits also 
showed a reduction in the number of implants and live foetuses and an 
increase in the number of skeletal abnormalities. The no-effect dose 
was 50 mg/kg b.w. in both species. 
15. The mutagenicity tests on bacteria (salm. typh.) and mammals in vivo 
(micronucleus - mice) proved negative. 
16. In man, clinical studies involving patients with osteoporosis showed 
that the average absorption was about 10%, of which 20% was excreted in 
the urine. Doses of 20 mg/kg/day for 6 to 12 days caused an increase in 
blood calcium and blood phosphorus and a reduction in bony tissue, 
accompanied by an increase in the excretion of calcium. 
17. The no-effect levels determined in different studies, whether acute or 
chronic, and in reproduction and teratogenicity studies were between 25 
and 50 mg/kg b.w. On this basis, applying a safety factor of 100, the 
acceptable daily intake (A.D.I.) in man was calculated to be between 
0.25 and 0.50 mg/kg b.w. 
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18. The first doses used in therapy were 5 mg/kg and the pharmacological 
effects in adults were clearly apparent at 20 mg/kg b.w./day. The 
corresponding dose for children was calculated at 2 mg/kg b.w./day. 
19. The Committee considered that the safety margin between the dose for 
cosmetic use in toothpastes and doses exerting a pharmacological and 
toxic effect was low, especially in children in whom undesirable 
reactions might be feared: normal use of a toothpaste containing 0.5% of 
the substance exposed a 20 kg child who ingested approximately 35% of it 
to an HEDP dose of some 6 mg, i.e. 0.3 mg/kg b.w./day. 
20. The Committee consequently felt able to accept the use of etidronic acid 
and salts thereof in mouth wash products, hair-care products and soaps 
under the conditions set out in section 2. 
However, only a majority of its members was able to give a favourable 
opinion on their use in toothpastes. 
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SUPPLEMENTARY OPINION 
on 
1,3-DIAMINOBENZENE (m-PHENYLENEDIAMINE) 
(Opinion delivered on 7 January 1986) 
1 . In i ts opinion delivered on 2 September 1980 ( 1 ) the Scientific Committee on 
Cosmetology deemed the use of 1,3-diaminobenzene (m-phenylenediamine) 
acceptable for use in hair dyes. 
2. In application of Article 12 of Directive 76/768/EEC on the approximation 
of the laws of the Member States relating to cosmetic products, which 
allows any Member State to prohibit provisionally the marketing of a 
cosmetic product in i ts terr i tory or subject i t to special conditions, i f 
i t finds on the basis of a "substantiated just i f icat ion" that this product, 
although complying with the requirements of the Directive, represents a 
hazard to health, a Member State prohibited the use of m-phenylenediamine 
in hair dyes in the light of the findings of recent experiments which 
indicate that: 
~ 1,3-diaminobenzene (m-phenylenediamine) and i ts oxidation products pass 
through the skin of rats and are excreted in the urine, 
- the elimination products induce frameshift mutations in microsomal tests 
on salmonella (AMES t e s t ) , 
- mutagenic act ivi ty is concentrated in two urine fractions, 
- mutagenic activity is higher in the urine of rats treated with the 
oxidized dye than in that of rats treated solely with m-phenylenediamine. 
3. Consequently, the Scientific Committee on Cosmetology reviewed the opinion 
i t delivered on 2 September 1980 in the light of these new findings. 
4. I t concluded that the experimental conditions of the studies referred to in 
paragraph 2 did not correspond to the conditions of cosmetic use in the 
following respects: 
(1) Report EUR 8634 
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1. The nature of the mixture applied: m-phenyLenediamine is never applied 
on its own or mixed solely with H_0_ in the dye mixture; the presence of 
precursors of the paratype is necessary for coloured pigments to form by 
oxidative copulation. The molecular size of the pigmented material 
formed and its relatively high molecular weight are not conducive to 
percutaneous penetration. 
2. The method of application: application for 24 hours on shaved skin and 
under occlusion is conducive to penetration compared to limited contact 
with the scalp for 30 minutes, before rinsing. 
3. The choice of the rat as the experimental animal, since its skin is much 
more permeable than the human skin. 
5. Consequently, the Scientific Committee on Cosmetology considers that, 
although these latest studies are interesting from a scientific point of 
view, they do not adduce any significant arguments which would cause it 
alter its opinion delivered on 2 September 1980. 
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FURTHER OPINION CONCERNING THE USE OF 
1,1,1-TRICHLOROETHANE IN COSMETIC PRODUCTS 
(Opinion expressed on 8 October 1985) 
The Committee has studied the arguments in favour of the safeguard clause 
that one Member State has applied to the use of 1,1,1-trichloroethane in 
cosmetic products. 
These arguments lack precision and are not considered convincing because 
the specific toxicity of 1,1,1-trichloroethane as a function of the 
dose/effect relationships, has not been clearly established; the effects 
mentioned namely on the kidneys, liver, heart, etc., have been observed 
only with very high doses and are reversible, while the inhalation 
exposure level in cosmetic use is very low ( ^ . 50 ppm). 
The Committee considers that it cannot express a final opinion until it 
receives the results of the National Cancer Institute's carcinogenicity 
studies; it also considers that, in the absence of further information, 
this compound constitutes no important immediate hazard and that its 
provisional authorization may be extended. 
In the meantime, it will examine the available toxicity data concerning 
the stabilizers employed, with due regard for any problems of synergy. 
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REPORT BY THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
ON THE USE OF CHLORQUINALDOL AS A PRESERVATIVE 
(Opinion delivered on 17 March 1986) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give its opinion on the use of chlorquinaldol as a preservative, at a 
maximum concentration of 0.05% in the finished cosmetic product. 
CONCLUSION 
The Committee cannot give an opinion on the basis of the available information. 
BACKGROUND 
1. Council Directive 76/768/EEC on the approximation of the laws of the Member 
States relating to cosmetic products, as last amended by Directive 
86/199/EEC, authorizes the placing on the market of cosmetic products 
containing as preservatives only the substances listed in Annex VI to the 
said Directive, within the limits and at the maximum concentrations laid 
down therein. 
2. The industry has requested that chlorquinaldol be included in the above-
mentioned Annex and has submitted a scientific dossier in support of the 
request. 
3. The Committee was therefore invited to deliver an opinion on the use of 
chlorquinaldol as a preservative at a maximum concentration of 0.05% in the 
finished cosmetic product. 
- 12 -
DISCUSSION 
4. 5,7-dichloro-2-methylchinolin-8-ol 
Synonyms : - Chlorquinaldol 
- Sterosan 
C10H7C12N0 
MW 228.08 
5. Practically insoluble in water : moderately soluble in organic solvents 
(chloroform, acetone, ether). 
6. Used as a preservative in cosmetics up to 0.05%. Also used at 3% in 
ointments and creams in medical and veterinary drugs as antiseptic and 
fungistatic. 
7. Oral LD50 values are 2.9 g/kg in rats, 0.583 g/kg in male mice and 
> 1.0 g/kg in dogs (males and females). 
Subcutaneous LD5Q values are 2.9 g/kg in male mice and 3.1 g/kg in female 
mice, in rats > 4.0 g/kg, in dogs > 0.5 g/kg. The intraperitoneal LD_Q 
values in mice are 0.185 g/kg in males, 0.185 g/kg in females, and in rats 
1.39 g/kg. 
8. Repeated dermal application of 0.05 ml of a 3% cream to the intact and 
scarified skin of hairless mice, daily for 28 days, only induced some 
reddening in 2/10 mice on a few days, while thickening of the skin was seen 
in 1/10 mice. More severe dermal reactions occurred in 90-day 
topical application studies in rabbits and dogs. 
9. An eye i r r i t a t ion test in rabbits with 0.1 ml cleansing milk containing 
0.02, 0.1 or 0.5% did not reveal clearly more eye changes than did the 
cosmetic without the test compound. 
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10. The substance is known to possess sensitizing potency for humans. In a 
study with 5558 patients, 2.4% were positive to a mixture of Vioform + 
Ste rosan. Cross sensitization of Sterosan with other halogenated 
hydroxyquinolines has been observed. 
11. The sub-chronic (90-day) dermal toxicity was examined in rabbits by applying 
0.7 g/kg b.w. of an ointment containing 0, 1, 3 or 10% of the test substance 
each day for 13 weeks (or 0, 7, 21 or 70 mg/kg b.w./day). In the top-dose 
group all animals died or were killed when moribund in the first 2 weeks. 
In the top-, and mid-dose group there were haematological changes, and blood 
was found in urine. Increases in blood urea-N, absence of spermiogenesis, 
and microscopical renal changes occurred in all treated groups. In this 
study, oral uptake was not fully excluded, but in a repeat study with the 
10% ointment under occlusion similar changes were found though less severe. 
12. A 90-day dermal study with the 0, 1, 3 and 10% ointments was also conducted 
in groups of 2 beagle dogs/sex treated with 7.0 g/dog on 7 days/week. 
In all treated groups the dogs showed dermal changes at the application 
sites, enhanced blood sedimentation rate and changes in white blood cell 
counts. In addition the 3 and 10% groups showed weight loss, increased 
numbers of leucocytes, increased activity of some blood enzymes and 
microscopical liver changes. 
14 
13. Dermal absorption studies with the C-labelled compound in guinea pigs in 
vivo showed that 96-98% of the dose, applied in various formulations, could 
still be removed from the skin after a 7-hr contact period. In humans 
treated with a cream, 96% was found not to have penetrated after 8 hrs. 
14. In vitro tests with intact skin from guinea pigs and from nude mice showed 
more penetration (20-30%) especially when the compound was applied in 
ethanol (40 and 50% respectively into skin of guinea pigs and nude mice). 
15. In a study in humans (exposed to Sterosan in ointments and creams), up to 
19.5% of a dermal dose was recovered in the urine, while after oral 
administration of an equal dose (30 mg) the mean urinary excretion (mainly 
in the form of the glucuronide) was 67.6%. 
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16. Embryotoxicity studies were conducted In rats and rabbits by dermal 
application of 0.5, 5.0/ 50.0 or 250.0 mg/kg b.w. in a 10% containing 
ointment under occlusion for 5 hours daily on days 7-16 of pregnancy in rats 
and on days 7-19 of pregnancy in rabbits. 
Apart from local irritation of the skin in the highest dose group of rats 
and in the two higher dose groups of rabbits, there were no other signs of 
intolerance. The reproduction data were not influenced by treatment. In 
the rat study several abnormalities of the skeleton were more frequent in 
the treatment groups than in controls, but it is stated that the incidences 
were in the normal range. 
The two higher dose groups in the rabbit study showed growth retardation 
which was attributed to the severe local skin damage. The higher incidence 
of a few bone abnormalities in the treated groups were not considered to 
represent embryotoxic or teratogenic effects. 
17. An Ames test with up to 100 ¿ig/plate was negative, but 5 ¿ig and above 
already caused growth depression or complete inhibition of the bacteria. In 
the mammalian cell culture HGPRT system with Chinese hamster ovary cell line 
V79 exposed up to 15 ¿ig/ml, no mutagenic activity was detected. The highest 
concentration tested was distinctly toxic. A micronucleus test in mice 
given once intraperitoneally 37.5, 75 or 150 mg/kg b.w., with bone marrow 
counts after 24, 48 and 72 hours did not reveal an increase in micronucleated 
cells. 
18. Information on systemic toxicity is avalable only from dermal studies 
conducted with small numbers of rabbits and dogs. In rabbits, mortality 
occurred with 70 mg/kg/day and haematological, hepatic and testicular 
changes with 21 mg/kg. The no-effect level is probably less than 7 mg/kg 
b.w. Results of dermal absorption studies vary widely. Of a dermal dose in 
humans, 19.5% has been recovered in the urine. A no-effect level should be 
established in a well conducted oral study in a sufficient number of rats. 
19. Evaluation is not possible on the basis of the available information. 
Information : Colipa dossier, Submission I, October 1985 
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REPORT BY THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
ON THE USE OF FORMALDEHYDE AND 
PARAFORMALDEHYDE IN COSMETIC PRODUCTS 
(Opinion delivered on 17 March 1986) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give its opinion on the use of formaldehyde and paraformaldehyde as 
preservative in cosmetic products under the conditions laid down by Directive 
76/768/EEC. 
CONCLUSION 
The Committee is of the opinion that, at the present time, there is 
insufficient evidence to change the use of formaldehyde and paraformaldehyde as 
preservative in cosmetic products under the conditions laid down by the 
directive 76/768/CEE. 
BACKGROUND 
1. Article 4 of Council Directive 76/768/EEC on the approximation of the laws 
of the Member States relating to cosmetic products, as last amended by 
Directive 86/199/EEC, requires Member States to prohibit the marketing of 
cosmetic products containing preservatives listed in Part I of Annex VI, 
save within the limits and under the conditions laid down in the Directive. 
2. In the case of formaldehyde and paraformaldehyde, these limits and 
conditions are : 
- Maximum authorized concentration : 0.2% (except for oral hygiene products) 
0.1% (for oral hygiene products) 
concentrations are expressed as free 
formaldehyde. 
- Limitations and requirements : Prohibited in aerosol dispensers, except 
for foams 
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- Conditions of use and warnings which must be printed on the Label : 
Contains formaldehyde (only if the concentration exceeds 0.05X). 
3. Under Article 12 of the Directive a Member State may provisionally prohibit 
the marketing of a cosmetic product in its territory or subject it to 
special conditions if it can show, on substantiated grounds, that although 
complying with the requirements of the Directive the product presents a 
hazard to health. In application of this Article, one Member State has 
prohibited the use of formaldehyde as an ingredient of cosmetic products, 
while authorizing the use of starting materials containing formaldehyde as a 
preservative provided that the concentration of that substance does not 
exceed 0.2% in the finished product. Under no circumstances, however, may 
formaldehyde be present in cosmetic products put up in aerosol form (except 
for foams) or in oral hygiene products. These measures are based on the 
opinion delivered by a committee of experts appointed by this Member State 
to study the carcinogenic, mutagenic and teratogenic effects of chemical 
compounds, which classified formaldehyde among the substances whose 
carcinogenicity is attested to by experimental but not by epidemiological 
evidence. 
4. The Committee was accordingly requested to deliver an opinion on the use of 
formaldehyde and paraformaldehyde as preservative in cosmetic products under 
the conditions set out in paragraphe 2 above. 
DISCUSSION 
5. Formaldehyde H - C = 0 
I 
H 
6. Easily soluble in water. 
7. Oral LD_~ values are 100 - 200 mg/kg in the rat, 260 mg/kg in the guinea pig 
and > 250 mg/kg in the dog. The dermal L D „ in the rabbit (270 mg/kg) is 
in the range of the oral LD5Q found in other species, suggesting 
considerable dermal absorption in rabbits. 
8. Formaldehyde is a severe eye irritant in the rabbit. In humans it is a 
moderate skin irritant and a strong sensitizer. Sensitizing properties may 
appear at use levels of c. 0.1%. Cases of pulmonary sensitization have been 
attributed to inhalation exposure of workers. 
.&* 
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9. The substance occurs naturally in foods. It is a normal metabolite in 
humans, and is rapidly oxidized and metabolized via formic acid to carbon 
dioxide and water. Some amino acids (tryptophan, serine, glycine) are 
endogenous sources of formaldehyde. 
10. Sub-chronic (90-day) administration of 50, 100 or 150 mg/kg b.w. in the 
drinking water of rats, and of 50, 75 or 100 mg/kg b.w. in the diet of dogs 
caused growth depression in the top-dose groups, but no gross or microscopic 
changes. 
11. Calves fed skimmed milk with 0.1% formalin (40% formaldehyde w/v) showed 
severe pathological changes in the stomach. No abnormalities were seen, 
however, in pigs fed skimmed milk with 0.15 or 0.5% formalin. 
12. In a 5-generation study in rats receiving 0.2% calcium formate in their 
drinking water, no changes were observed in growth rate, or reproduction , 
nor in gross- or microscopic pathology. Neither were abnormalities seen 
when hexamethylene tetramine (HMT) was administered in the drinking water 
over 5 generations of rats at levels of 5 or 50 mg/kg body weight. 
13. Treatment of mice with up to 185 mg/kg by gavage on day 6-15 of gestation 
did not induce signs of embryotoxicity or teratogenicity although the high 
dose was toxic to the dams. 
No teratogenic effects were observed in a dog study by administering 3.1 or 
9.4 mg formaldehyde/kg/day or 15 to 31 mg HMT/kg/day during pregnancy. 
14. Several long-term oral studies have been conducted in rats or mice. In one 
mouse study, females showed a slightly increased tumour incidence with 1% 
HMT or 0.15% formaldehyde in the drinking water. The other oral studies 
were negative. 
15. Two recent initiation-promotion studies in mice, using traditional two-stage 
skin painting techniques, have been reported. In one study (Krivanek et 
al., 1983), formaldehyde lacked either initiation or promotor activity after 
180 days of observation. In the second study Spang1er and Ward (1983) 
reported that through 48 weeks of observation, formaldehyde showed no 
activity as an initiator or as a complete carcinogen, but may have had weak 
promoting activity. 
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16. Dermal absorption is relatively small. In rats c. 5% of the labelled 
substance was absorbed from an oil in water cream within 48 hours (Barnik et 
al. 1985). 
17. The inhalation LCsn for rats was 250 ppm. In humans, signs of discomfort 
(irritation of nose and throat, lachrymation) occur when the respirated air 
contains 4 ppm. Sub-chronic (90-day) exposure of rats to 3.8 ppm in air 
resulted in interstitial pneumonia. In recent chronic inhalation studies 
with 2, 6 and 15 ppm in air, squamous cell carcinoma of the nasal cavity 
were induced in rats and mice. Exposure levels causing nasal tumours also 
caused pathological changes in the nasal mucosa. No nasal tumours occurred 
upon chronic inhalation exposure of hamsters to 10 ppm. 
18. Formaldehyde induces chromosomal aberrations and DNA damage in several test 
systems including mammalian cells in culture, and is mutagenic to bacteria, 
yeasts and the fruit fly, but not to the silkworm, or to mammalian cells in 
culture. One dominant lethal study in mice was positive, another study was 
negative. 
19. The possible carcinogenicity of formaldehyde in man has been discussed at a 
recent meeting of a WHO Working Group in Dubrovnik (1985). At least 10 
different epidemiological studies were evaluated, of which several indicated 
an excess of tumours. However, in different studies different sites were 
involved. 
Moreover, the best designed studies were negative. In one study on more 
than 1000 deceased embalmers in New York a significant excess of deaths from 
skin cancer was found (based on 8 cases). Such an effect was not found in a 
similar study conducted in California (Hopkins 1985). In spite of the great 
number of studies available, the evidence was considered insufficient to 
assess the carcinogenic potency of formaldehyde in humans (WHO 1985). This 
confirms the conclusions drawn by IARC in 1982. 
20. Formaldehyde is an irritant and a sensitizer. Repeated oral exposure of 
rats, mice, and dogs to relatively high levels is well tolerated. The 
substance possesses mutagenic properties. Carcinogenic properties have been 
established upon inhalation by rats and mice of relatively low levels, 
which, however, exerted a cytotoxic effect. There is no evidence to 
consider formaldehyde a dermal carcinogen, but a long term dermal exposure 
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study in animals is not available. The substance is on the list of accepted 
preservatives in cosmetics at levels up to 0.2%. At the present time there 
is insufficient evidence to change this situation. 
21. Information from : - Data sheet Council of Europe 
- Data sheet Nat. Inst. Public Health, the Netherlands 
- JECFA 17th Report, WHO Techn. Rep. Series 1974, No. 539 
- IARC Monographs 29 (1982) 345-389 
- WHO Working group on indoor air quality : radon and 
formaldehyde. Dubrovnik, 26-30 Aug. 1985. 
Summary report. 
- Bartnik et al. (1985) Toxicol. Letter's 25, 167-172 
- Krivanek, N.D. et al. (9183) Chapter 6 in : 
Formaldehyde-toxicology, epidemiology, mechanisms. Ed. 
J.J. Clary et al. Marcel Dekker Inc., New York/Basel 
- Spangler and Ward (1983) Chapter 5 in : Formaldehyde 
toxicology, epidemiology, mechanisms. Ed. J.J. Clary et 
al., Marcel Dekker Inc., New York/Basel 
- Squire and Cameron 1984, Regulatory Toxicol. 
Pharmacol. 4, 107-129 
- Hopkins (1985), J. Fd. Chem. Toxicol. 23 (11) 1024-1026 
- 20 -
REPORT OF THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
ON THE USE OF 8-HYDR0XYQUIN0LINE AND ITS SULPHATE 
IN COSMETIC PRODUCTS 
(Opinion delivered on 7 January 1986) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give its opinion on the use of 8-hydroxyquinotine and its sulphate in 
cosmetic products as a stabilizer for hydrogen peroxide in hair-care 
preparations at the maximum authorized concentration of 0.3% (calculated as 
base) in the finished product. 
CONCLUSION 
The Committee is of the opinion that the use of 8-hydroxyquinoline and its 
sulphate in cosmetic products as a stabilizer for hydrogen peroxide can be 
accepted for rinsed off products under the conditions laid down in Directive 
76/768/EEC. For non rinsed off products information is requested on skin and 
eye irritating properties, on dermal absorption and teratogenicity. However, 
on the basis of the data available, the Committee could accept, for the time 
being, the use in non rinsed off products under the same conditions. 
BACKGROUND 
1. Article 4 of Directive 76/768/EEC on the approximation of the laws of the 
Member States relating to cosmetic products, as last amended by Directive 
85/391/EEC, requires Member States to prohibit the placing on the market of 
cosmetic products containing substances listed in Part I of Annex III, save 
within the limits and under the conditions laid down therein. 
2. In the case of 8-hydroxyquinoli ne and its sulphate, these limits and 
conditions are : 
- Field of application and/or use : As a stabilizer for hydrogen peroxide in 
rinse-off hair-care preparations. 
- Maximum authorized concentration 
in the finished product : 0.3% calculated as base 
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3. The industry has requested that the f ie ld of application and/or use be 
extended to non-rinse-off hair-care preparations. 
4. The Committee was accordingly invited to deliver an opinion on the use of 
8-hydroxyquinoline and i ts sulphate as a stabil izer for hydrogen peroxide in 
hair-care preparations at the maximum authorized concentration of 0.3% 
(calculated as base) in the finished product. 
DISCUSSION 
5. Hydroxyquinoline is insoluble in water and ether, slightly soluble in other 
organic solvents; the sulphate dissolves well in water. 
6. Used in cosmetics at dose levels of 0.3% as stabilizer for hydrogen peroxide 
in hair-care preparations (rinsed off and non rinsed off). 
7. LD_0 values reported are : oral in rats 1.2 g/kg, in guinea pigs > 1.2 g/kg 
for the free base; i.V. in mice 50 mg/kg, in rabbits 65 mg/kg for the free 
base; s.c. in mice 25 mg/kg, in rats 200 mg/kg for the sulphate; i.p. in 
mice 43 mg/kg. 
8. Sensitizing properties have been reported from studies in man. 
9. Oral administration to dogs resulted in rapid intestinal absorption and 
renal excretion and slow excretion in the bile. 
10. Intravenous treatment of rabbits with a single dose of 8-hydroxyquinoline in 
amounts of 10 - 50 mg/kg resulted in destruction of the ß-cells in the 
pancreas and increased blood glucose levels. Pancreatic damage was observed 
also in several other species upon i.v. administration. 
11. Feeding rats 400 mg/kg b.w. for 16 weeks caused hemosiderosis in the liver 
and spleen. In another rat feeding study hepatotoxicity and renal toxicity 
occurred on diets providing 100-250 mg/kg b.w. for 30-40 days. 
12. In 1977 IARC examined several carcinogenicity studies in mice and rats 
conducted by oral, subcutaneous and intravaginal administration, and in mice 
by skin application and bladder implantation. These studies were considered 
of limited value for various reasons and no evaluation could be made of the 
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carcinogenicity of this substance. Meanwhile further Longterm studies were 
conducted and reported recently by NTP (1985). Groups of 50 rats/sex and of 
50 mice/sex were fed diets containing 0, 1500 and 3000 ppm of the test 
substance. The top-dose groups showed relatively low body weights. No 
significant differences in mortality occurred between groups in either 
species. Extensive gross and microscopic pathology did not reveal 
treatment-related changes and there was no evidence of carcinogenic 
properties. Haematological and clinical examinations were not conducted. 
13. The substance showed mutagenic properties in the Ames test. A test on 
induction of aneuploidy in Nuerospora crassa was equivocal. Chromosome 
aberrations were observed in root tips of Vicia faba, and in bone marrow 
cells of mice after i.p. injection of 40 mg/kg b.w. Equivocal or 
inconclusive results were obtained in a variety of other short-term tests 
such as a Drosophila test, a micronucleus test in mice and a chromosome 
aberration test in human leucocytes in vitro. 
14. No information is available on skin or eye irritation, on dermal toxicity or 
on dermal absorption. Information on reproductive effects or teratogenicity 
is also absent. The substance seems to be relatively harmless because 1500 
ppm in the diet of rats (75 mg/kg b.w.) and in the diet of mice (150 mg/kg 
b.w.) was a no effect level. Therefore, the substance can be accepted for 
rinsed off products. However for non rinsed off products information is 
requested on skin and eye irritating properties, on dermal absorption and 
teratogenicity. 
Information : - Data sheet National Institute of Public Health, 
the Netherlands 
- IARC Monograph 13 (1977) 101-112 
- NTP Technical Report Series No. 276, April 1985. 
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REPORT BY THE SCIENTIFIC COMMITTEE ON COSMETOLOGY 
ON THE USE OF HEXACHLOROPHENE IN COSMETIC PRODUCTS 
(Opinion delivered on 17 March 1986) 
TERMS OF REFERENCE OF THE COMMITTEE 
To give its opinion on the use of hexachlorophene in cosmetic products under 
the conditions Laid down by Directive 76/768/EEC. 
CONCLUSION 
In view of the toxic properties and considerable dermal absorption of 
hexachlorophene, and the possible presence of TCDD, the Committee cannot 
recommend the use of hexachlorophene in cosmetics. 
BACKGROUND 
1. Article 4 of Council Directive 76/768/EEC on the approximation of the laws 
of the Member States relating to cosmetic products, as last amended by 
Directive 86/199/EEC, requires Member States to prohibit the placing on the 
market of cosmetic products containing preservatives listed in Part I of 
Annex VI, save within the limits and under the conditions laid down in the 
Directive. 
2. In the case of hexachlorophene, these limits and conditions are : 
- Maximum authorized concentration : 0.1% 
- Limitations and requirements : Prohibited in products for children under 
three years of age and in intimate hygiene 
products. 
- Conditions of use and warnings which must be printed on the label : 
Not to be used for children under three years of age. Contains 
hexachlorophene. 
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3. Certain Member States would Like to discourage or even prohibit the use 
of hexachlorophene in cosmetic products, 
4. The Committee was accordingly invited to deliver an opinion on the use of 
hexachlorophene in cosmetic products under the conditions laid down in 
paragraph 2 above. 
DISCUSSION 
5. 2,2 l -Methylenebis[3,4,6- t r ich lorophenol ] 
Synonym : Hexachlorophene 
Cl OH Cl CI C1SH8C1602 
MW 1*06.92 
6. Soluble in ethanol, ether and other organic solvents, practically insoluble 
in water. 
7. Acute effects 
Oral LD,-n values (in mg/kg) are : 66 in male rats, 56 in female rats, 120 in 
weanling rats, 9 in suckling rats. 
A single oral dose of 100 mg/kg may paralyse weanling rats. In children, a 
single oral dose of 250 mg/kg may be fatal. 
A single dermal dose of 600 mg/kg in ethanol may kill rats. 
Vigorous washing of pigs with 3% in detergent, once, for 20 minutes, induced 
hind limb weakness five days later. 
Intravenous injection of monkeys, rabbits, dogs and cats with respectively 
8.0, 5.0, 10 and 10 mg/kg induced severe pharmacological effects and death. 
8. Eye i r r i t a t i o n 
A test in rabbits with 0.1 ml 2% solution of the monosodium salt in 4% 
aqueous propylene glycol was negative. 
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9. Primary skin irritation 
Tests with 0.1% and above in acetone were positive in guinea pigs and 
rabbits, 0.05% and above was positive in 1/10 rabbits. The irritation 
reaction reached a maximum after 4 days. The irritating potency was less in 
other vehicles, such as propylene glycol, petrolatum, olive oil, and 
polyethylene glycol 400. Irritation occurred, however, in each of the 
vehicles if the concentration was 1.0%. In humans 0.1% in propylene glycol 
caused irritation, while 10% did not if the vehicle was petrolatum, olive 
oil, isopropylmyristate, or polyethylene glycol 400 (Horikawa et al. 1974). 
10. Phototoxicity tests in rabbits and guinea pigs were positive, inasfar the 
primary skin irritation reaction caused by 0.1% in acetone was consistently 
more pronounced on skin sites treated topically and then irradiated with UV, 
than on skin sites treated topically and not irradiated. 
11. Sensitization. A sensitization and a photosensitization test in guinea 
pigs, which were induced topically with 0.05 ml 2% in acetone, daily for 5 
days/week during 2 weeks, and challenged with 0.05 ml 0.001 to 0.1% in acete 
was negative (Morikawa et al.1974). 
12. Oral short-term 
- Rats treated orally with 40 mg/kg/day for 14 days showed paralysis and 
blood levels of 4 - 6 ppm. When the rats were treated for 42 days with 40 
mg/kg/day, 7/30 rats died. Microscopic changes, mainly vacuolization, 
were observed in the brain and spinal cord. These lesions disappeared 
slowly ( 84 days) after treatment. Blood levels were 1 - 8 ppm on day 42. 
- Similar effects have been observed in mice, dogs, rabbits and monkeys 
after repeated oral dosing with 25 - 100 mg/kg. 
- Daily oral dosing of rats with 20 mg/kg b.w. for 6 weeks caused spongy 
vacuolation in the cerebrum and cerebellum (NIPH). 
- Rats fed 500 ppm in the diet (25 mg/kg b.w.) showed nervousness and 
weakness in the hindquarters after 14 days. These clinical signs 
developed into paralysis within a few weeks after treatment. 
- A 90-day rat feeding study with 0, 20, 65 and 200 ppm resulted in 
vacuolation of the cerebrum and spinal cord in the top-dose group, 
increased liver weight in the mid-dose group, and no changes in the low-
dose group. Blood levels of HCP ranged from 0.5 - 3.0 ppm in the treated 
groups (NIPH). 
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13. Dermal short-term 
- Rats treated twice daily with 1 ml 3% HCP in detergent or vegetable oil 
died within 2 - 1 5 days with symptoms of CNS-damage. Similar signs 
occurred if the treated sites were washed after 25 minutes (NIPH). 
- Young rats (age 0 - 3 3 days) were immersed (except the head) in 3% HCP for 
15 sec. daily, then rinsed with water for 5 sec. and then dried. Clinical 
signs developed in all rats within 22 days, the younger the rats, the 
smaller the number of treatments needed. Death occurred in 25% of the 
treated animals (Delcour-Firquet, 1980). 
- Monkeys treated derma Ily with 0, 5, 20 or 80 mg/kg (as a solution in 
propylene glycol/ethanol) twice weekly for 3 months developed various 
signs of intoxication including spongy degeneration of CNS with 80 and 
20 mg/kg, while 5 mg/kg was not a clear NEL. 
- CNS symptoms developed also in a normal infant after daily treatment for 4 
days with 3% HCP in a lotion. 
14. Dermal absorption 
14 
- In r a t s , 25 - 55% of a dose of C-labelled HCP was found to pass through 
the in tac t s k i n , depending on the veh ic le , the sex and the age. Upon 
r ins ing with acetone immediately a f te r app l i ca t ion , 13% remained bound to 
the sk in . 
- Rat skin is more permeable than skin of guinea pigs or p igs . 
- Upon top ica l appl icat ion in acetone to the skin of rats and guinea pigs 
without r ins ing 76.6% and 66.9% respect ively was recovered in the organs 
and carcass. 
- Dermal absorption is rapid in human babies. 
- Many cases of rapid in tox ica t ion have been observed upon applying HCP as a 
desinfectant to burnt sk in . In these condit ions blood levels varied 
between 2 and 17/jg/ml (Delcour-Firquet, 1980). 
- The use of a 3% HCP so lu t ion as a body and hand soap led to blood levels 
ranging from 0.005 - 0 .38 / jg /ml . Use of a soap with 0.75Z HCP resulted in 
blood levels from 0.02 - 0 .14 / ig /m l . Upon use of a »outh wash with 0.5% 
HCP for 3 weeks blood levels of 0.02 - 0.12 pg/al were Measured. 
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15. Reproduction 
- Feeding rats 0, 20 or 100 ppm in the diet (0, 1 or 5 mg/kg b.w.) for 
successive generations did not affect the microscopy of the CNS. With 100 
ppm, survival of pups was decreased in the F1 generation. No such effect 
was noticed in F2 generation rats (NIPH). 
- In a 3-generation study in rats 50 ppm in the diet d id not induce any 
e f f e c t . 
16. Teratogenicity 
- Rabbits which received orally 0, 3 or 6 mg/kg b.w. on day 6 through 18 of 
pregnancy did not show an effect on foetal survival. In the top-dose 
group 2/62 foetuses were grossly abnormal (acrania and ectopic teratosis). 
- In another similar study in rats with 6 mg/kg none of the foetuses were 
structurally abnormal. Apart from delayed ossification, skeletal 
examination was negative (NIPH). 
- Rats treated with 500 ppm in the diet, or with 20 - 30 mg/kg b.w./day by 
gavage caused some malformations (angulated ribs, cleft palate, micro- and 
anophthalmia) and reduction in litter size. These dose levels approached 
those which caused maternal death. 
- Pregnant rats treated with a 45% suspension of HCP in the vagina showed 
maternal toxicity and major malformations in some embryos. 
- Subcutaneous injection of mice with 12.5 or 25 mg/kg b.w./day on days 3-8, 
7-12 or 11-17 of gestation caused foetal resorptions but no malformations 
(IARC). 
- Babies from hospital personnel who had been exposed to HCP during 
pregnancy showed an increased incidence of severe and minor malformations 
(IARC). 
17. Metabolism 
- Upon oral administration of HCP to rats, 80 - 90% is excreted unchanged in 
the faeces within 10 days. However, upon i.p. administration, extensive 
biliary excretion (31-47% of the dose within 24 hours) and enterohepatic 
circulation occurred. The principal metabolite in bile was the 
monoglucuronide. Much of the unchanged compound found in the faeces 
probably resulted from intestinal bacterial hydrolysis of the conjugate 
(IARC). 
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- Upon dermal administrat ion to rats c. 70% of t o t a l rad ioac t i v i t y was 
recovered i n the faeces, 9% in the ur ine. In the urine 33-81% of the 
rad ioac t i v i t y was of the unchanged HCP. 
- Dermal appl icat ion to the monkey resulted in 40% in faeces and 19% in 
u r ine . Unchanged HCP in urine was 83-100% of rad ioac t i v i t y in u r ine . 
18. Mutagenicity 
- A host-mediated assay in rats fed 100 or 200 ppm in the diet for 90 days 
showed no reverse mutations in S.typh. G 46. 
- No dominant lethal mutations were detected in male mice treated with 2.5 
or 5.0 mg/kg b.w. by i.p. injections and subsequently mated with untreated 
females. 
- A chromosomal aberration test with human Leucocytes exposed to HCP in 
vitro at levels of 1-200 mg/l for 6-21 hrs was negative. However, mitosis 
was suppressed with a concentration as low as 40 mg/l applied for 6 hrs 
(IARC). 
19. Carcinogenicity 
- Rats fed 0, 17, 50 or 150 ppm in the diet for 2 years showed no increased 
incidence of tumours (IARC). 
- No indications of carcinogenic properties were observed : 
a) upon feeding 50 ppm in the diet of rats for 2 years; 
b) upon feeding 150 ppm in the diet of C57B mice, or of XVII/G mice for 
nearly 2 years and 1 1/2 years respectively; 
c) upon administration (route not indicated) of 0.5 mg daily for 20 days 
to 7 pregnant mice of the XVII/G strain and observing the descendents 
for 11/2 years; 
d) upon s.c. administration to mice of the XVII/G strain of 0.05, 0.05 and 
0.1 mg on day 1, 2 and 8 after birth respectively and then observing 
these mice for their lifetime (Rudalli and Assa 1978). 
- Skin painting of mice twice weekly for their lifetime with 0.02 ml acetone 
containing 1, 5 or 10 mg HCP caused ulceration, necrosis, inflammation of 
the skin and neurological symptoms. High mortality occurred in the 
treated groups but there was no increase in incidence of tumours (IARC 
1979). 
- 2 9 -
20. HCP is of considerable to high toxic i ty . The major effect is a degenerative 
change of the CNS that may occur both upon dermal and oral exposure. Dermal 
absorption is considerable. Systemic effects upon dermal or oral exposure 
are the same. Excessive use of skin-care products containing HCP, may 
result in high blood levels, c l in ical signs of intoxication, damage to the 
CNS and death. The no-effect-Level was 1 mg/kg b.w. in a 90-day oral 
toxicity study in rats. In monkeys treated by subcutaneous inject ion, twice 
weekly, for 3 months, the NEL was 5 mg/kg. The substance has shown 
teratogenic properties but no mutagenic or carcinogenic potency. Commercial 
preparations may contain the extremely toxic TCDD as a contaminant. In view 
of the toxic properties and considerable dermal absorption of HCP, and the 
possible presence of TCDD/ the use of HCP in cosmetics cannot be 
recommended. 
Information : - Data sheet National Inst i tute of Public Health, the Netherlands 
(1972) (NIPH) 
- Morikawa et a l . J . Soc. Cosmet. Chem. 25 (1974) 113-130 
- M.P. Delcour-Firquet, La toxicité de l'hexachlorophène, Arch. 
Bel. Med. Soc. Hyg., Med. Travai l , Med. Legale, 38 (1980) 1-43 
- IARC Monographs Vol 20 (1979) 
- Rudalli , G. and R. Assa, Cancer Letters 5(1978) 325-332. 
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